Form 8-K - Current report:
SEC Accession No. 0001104659-20-025054
Filing Date
2020-02-26
Accepted
2020-02-26 08:01:27
Documents
6
Period of Report
2020-02-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm209716d3_8k.htm 8-K 34461
2 EXHIBIT 4.1 tm209716d3_ex4-1.htm EX-4.1 105576
3 EXHIBIT 5.1 tm209716d3_ex5-1.htm EX-5.1 15586
4 EXHIBIT 10.1 tm209716d3_ex10-1.htm EX-10.1 107982
5 EXHIBIT 10.2 tm209716d3_ex10-2.htm EX-10.2 224474
6 GRAPHIC logo.jpg GRAPHIC 5613
  Complete submission text file 0001104659-20-025054.txt   497166
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

IRS No.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 20653343
SIC: 2834 Pharmaceutical Preparations